These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37056483)

  • 1. Longitudinal analysis of anti-SARS-CoV-2 neutralizing antibody (NAb) titers in vaccinees using a novel giant magnetoresistive (GMR) assay.
    Ng E; Choi C; Wang SX
    Sens Actuators B Chem; 2023 Jul; 387():133773. PubMed ID: 37056483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
    Goodhue Meyer E; Simmons G; Grebe E; Gannett M; Franz S; Darst O; Di Germanio C; Stone M; Contestable P; Prichard A; Reik R; Vassallo R; Young P; Busch MP; Williamson P; Dumont LJ
    Transfusion; 2021 Apr; 61(4):1160-1170. PubMed ID: 33554362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination.
    Wang F; Huang B; Lv H; Feng L; Ren W; Wang X; Tang L; Liu Q; Wu D; Zheng H; An Z; Deng Y; Zhao L; Ye F; Wang W; Zhang H; Chang S; Liao Y; Chen F; Rodewald LE; Gao GF; Yin Z; Tan W
    Front Immunol; 2022; 13():967051. PubMed ID: 36159863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment.
    Takahashi M; Saito K; Ai T; Nojiri S; Khasawneh A; Paran FJ; Horiuchi Y; Takei S; Yamamoto T; Wakita M; Hiki M; Miida T; Naito T; Takahashi K; Tabe Y
    PLoS One; 2023; 18(1):e0279779. PubMed ID: 36693058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
    Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
    Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan.
    Huang YF; Hsu FC; Wu JJ; Lin YL; Liu MT; Yang CH; Kuo HS; Chen YJ; Cheng CY; Lin HH; Liao CC; Chang CS; Liang JJ; Cheng WY; Huang JC; Chen CP; Cheng SH; Lin YC; Yang SH; Chou YJ
    J Microbiol Immunol Infect; 2023 Jun; 56(3):506-515. PubMed ID: 36967265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An automated chemiluminescent immunoassay (CLIA) detects SARS-CoV-2 neutralizing antibody levels in COVID-19 patients and vaccinees.
    Liu B; Su X; Yu G; Yang S; Wang F; Huang T; Zhou L; Hui Z; Liao Y; Qiu Y; Huang J; Gao H; Liu J; Zhong Y
    Int J Infect Dis; 2022 Feb; 115():116-125. PubMed ID: 34896578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Antibody Responses Among Residents and Staff of Long-Term Care Facilities in the State of New Jersey During the First Wave of the COVID-19 Pandemic.
    Friedman SM; Li J; Thomas P; Gurumurthy M; Siderits R; Nepomich A; Lifshitz E
    J Community Health; 2023 Feb; 48(1):50-58. PubMed ID: 36197535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
    Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
    PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Evaluation of a Rapid Neutralizing Antibody Assay for COVID-19 Vaccination.
    Yu H; Liu H; Yang Y; Guan X
    ACS Omega; 2022 Oct; 7(41):36254-36262. PubMed ID: 36278077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination.
    Guiomar R; Santos AJ; Melo AM; Costa I; Matos R; Rodrigues AP; Kislaya I; Silva AS; Roque C; Nunes C; Aguiar J; Graça F; Silva Graça A; Machado A
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
    Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
    Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients.
    Zhang H; Jia Y; Ji Y; Cong X; Liu Y; Yang R; Kong X; Shi Y; Zhu L; Wang Z; Wang W; Fei R; Liu F; Lu F; Chen H; Rao H
    Front Microbiol; 2022; 13():816778. PubMed ID: 35359732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference.
    Graninger M; Jani CM; Reuberger E; Prüger K; Gaspar P; Springer DN; Borsodi C; Weidner L; Rabady S; Puchhammer-Stöckl E; Jungbauer C; Höltl E; Aberle JH; Stiasny K; Weseslindtner L
    Microbiol Spectr; 2023 Feb; 11(1):e0231422. PubMed ID: 36622205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.